Top

Irish Journal of Medical Science (1971 -)

Published in:

27-07-2022 | Stroke | Original Article

Reminiscence therapy is a feasible care program for improving cognitive function, anxiety, and depression in recurrent acute ischemic stroke patients: a randomized, controlled study

Authors: Jiaying Yu, Yun Tang, Jingfeng Han, Jiawei Chen, Weiwei Lin, Wei Cui

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2023

Abstract

Objective

Reminiscence therapy provides benefits among first-episode acute ischemic stroke (AIS) patients and their caregivers. This study intended to further compare the effect of reminiscence therapy plus usual care (RTUC) and usual care (UC) on cognitive function, anxiety, and depression among recurrent AIS patients.

Methods

Totally, 160 recurrent AIS patients were enrolled and randomized in a 1:1 ratio into the RTUC group (N = 81) and UC group (N = 79), then a 12-month corresponding intervention was conducted in each group. Mini-Mental State Examination (MMSE) score and Hospital Anxiety and Depression Scale (HADS) were evaluated on discharge (M0), at month (M) 3, M6, M9, and M12 after discharge.

Results

MMSE scores at M6 (27.0 ± 1.6 vs. 26.3 ± 2.3, P = 0.031) and M12 (27.0 ± 1.7 vs. 26.1 ± 2.4, P = 0.009) were elevated, while cognitive impairment rate at M12 (29.2% vs. 45.7%, P = 0.042) and cognitive impairment severity at M12 (P = 0.029) were declined in RTUC group compared to UC group. Meanwhile, the HADS-anxiety scores at M9 (5.7 ± 3.1 vs. 6.9 ± 4.0, P = 0.046) and M12 (5.6 ± 2.7 vs. 7.0 ± 4.3, P = 0.024), anxiety rate at M12 (22.2% vs. 38.2%, P = 0.039) and anxiety severity at M12 (P = 0.018) were declined in RTUC group compared to UC group. Besides, the HADS-depression score at M12 (5.7 ± 3.1 vs. 6.8 ± 3.3, P = 0.043) was decreased in RTUC group compared to UC group, but depression rate and severity were not different between the two groups at each visit point (all P > 0.05).

Conclusion

RTUC program elevates cognitive functions and alleviates mental problems in recurrent AIS patients.

Available only for authorised users

Petty K, Lemkuil BP, Gierl B (2021) Acute ischemic stroke. Anesthesiol Clin 39(1):113–125. https://doi.org/10.1016/j.anclin.2020.11.002CrossRefPubMed

Popiela TJ, Krzysciak W, Pilato F et al (2022) The assessment of endovascular therapies in ischemic stroke: management, problems and future approaches. J Clin Med 11(7). https://doi.org/10.3390/jcm11071864

Rabinstein AA (2020) Update on treatment of acute ischemic stroke. Continuum (Minneap Minn) 26(2):268–286. https://doi.org/10.1212/CON.0000000000000840CrossRefPubMed

Toi S, Shirai Y, Ishizuka K et al (2022) Recurrent stroke incidence and etiology in patients with embolic stroke of undetermined source and other stroke subtypes. J Atheroscler Thromb 29(3):393–402. https://doi.org/10.5551/jat.61895CrossRefPubMed

Delgado J, Masoli J, Hase Y et al (2022) Trajectories of cognitive change following stroke: stepwise decline towards dementia in the elderly. Brain Commun 4(3):fcac129. https://doi.org/10.1093/braincomms/fcac129

Kalaria RN, Akinyemi R, Ihara M (2016) Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta 1862(5):915–925. https://doi.org/10.1016/j.bbadis.2016.01.015CrossRefPubMedPubMedCentral

Abu Khait A, Reagan L, Shellman J (2021) Uses of reminiscence intervention to address the behavioral and psychosocial problems associated with dementia: an integrative review. Geriatr Nurs 42(3):756–766. https://doi.org/10.1016/j.gerinurse.2021.03.021CrossRefPubMed

Macleod F, Storey L, Rushe T, McLaughlin K (2021) Towards an increased understanding of reminiscence therapy for people with dementia: a narrative analysis. Dementia (London) 20(4):1375–1407. https://doi.org/10.1177/1471301220941275CrossRefPubMed

Lok N, Bademli K, Selcuk-Tosun A (2019) The effect of reminiscence therapy on cognitive functions, depression, and quality of life in Alzheimer patients: randomized controlled trial. Int J Geriatr Psychiatry 34(1):47–53. https://doi.org/10.1002/gps.4980CrossRefPubMed

10.

Saragih ID, Tonapa SI, Yao CT et al (2022) Effects of reminiscence therapy in people with dementia: a systematic review and meta-analysis. J Psychiatr Ment Health Nurs. https://doi.org/10.1111/jpm.12830CrossRefPubMed

11.

Li A, Liu Y (2022) Reminiscence therapy serves as an optional nursing care strategy in attenuating cognitive impairment, anxiety, and depression in acute ischemic stroke patients. Ir J Med Sci 191(2):877–884. https://doi.org/10.1007/s11845-021-02600-8CrossRefPubMed

12.

Cheng C, Fan W, Liu C et al (2021) Reminiscence therapy-based care program relieves post-stroke cognitive impairment, anxiety, and depression in acute ischemic stroke patients: a randomized, controlled study. Ir J Med Sci 190(1):345–355. https://doi.org/10.1007/s11845-020-02273-9CrossRefPubMed

13.

Jauch EC, Saver JL, Adams HP Jr et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44(3):870–947. https://doi.org/10.1161/STR.0b013e318284056aCrossRefPubMed

14.

Liu X, Yuan K, Ye X, Liu R (2021) Proposing a novel care program: reminiscence therapy involved care for anxiety, depression, and quality of life in postoperative cervical cancer patients. Ir J Med Sci. https://doi.org/10.1007/s11845-021-02728-7CrossRefPubMedPubMedCentral

15.

Mahendran R, Gandhi M, Moorakonda RB et al (2018) Art therapy is associated with sustained improvement in cognitive function in the elderly with mild neurocognitive disorder: findings from a pilot randomized controlled trial for art therapy and music reminiscence activity versus usual care. Trials 19(1):615. https://doi.org/10.1186/s13063-018-2988-6CrossRefPubMedPubMedCentral

16.

Cumming TB, Churilov L, Linden T, Bernhardt J (2013) Montreal Cognitive Assessment and Mini-Mental State Examination are both valid cognitive tools in stroke. Acta Neurol Scand 128(2):122–129. https://doi.org/10.1111/ane.12084CrossRefPubMed

17.

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370. https://doi.org/10.1111/j.1600-0447.1983.tb09716.xCrossRefPubMed

18.

Perna R, Harik L (2020) The role of rehabilitation psychology in stroke care described through case examples. NeuroRehabilitation 46(2):195–204. https://doi.org/10.3233/NRE-192970CrossRefPubMed

19.

Li M, Lyu JH, Zhang Y et al (2020) Efficacy of group reminiscence therapy on cognition, depression, neuropsychiatric symptoms, and activities of daily living for patients with Alzheimer Disease. J Geriatr Psychiatry Neurol 33(5):272–281. https://doi.org/10.1177/0891988719882099CrossRefPubMed

20.

Redulla R (2020) Reminiscence therapy for dementia. Issues Ment Health Nurs 41(3):265–266. https://doi.org/10.1080/01612840.2019.1654572CrossRefPubMed

21.

Liu X, Cheng C, Liu Z et al (2021) Longitudinal assessment of anxiety/depression rates and their related predictive factors in acute ischemic stroke patients: a 36-month follow-up study. Medicine (Baltimore) 100(50):e28022. https://doi.org/10.1097/MD.0000000000028022

22.

Cuevas PEG, Davidson PM, Mejilla JL, Rodney TW (2020) Reminiscence therapy for older adults with Alzheimer’s disease: a literature review. Int J Ment Health Nurs 29(3):364–371. https://doi.org/10.1111/inm.12692CrossRefPubMed

Title: Reminiscence therapy is a feasible care program for improving cognitive function, anxiety, and depression in recurrent acute ischemic stroke patients: a randomized, controlled study
Authors: Jiaying Yu
Yun Tang
Jingfeng Han
Jiawei Chen
Weiwei Lin
Wei Cui
Publication date: 27-07-2022
Publisher: Springer International Publishing
Keywords: Stroke
Mood Disorders
Care
Affective Disorder
Anxiety
Published in: Irish Journal of Medical Science (1971 -) / Issue 3/2023
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-022-03114-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Magnesium implants in orthopaedic surgery create a diagnostic conundrum: A radiology case series and literature review

Menstrual abnormalities post-COVID vaccination: a cross-sectional study on adult Lebanese women

Dietary practices, beliefs and behaviours of adults with inflammatory bowel disease: a cross-sectional study

Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study

Correction to: Child protection concern in patients during the COVID‑19 lockdown

A constellation of dermatological findings in a COVID-19 positive patient

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials